Work

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy

Year: 2017

Type: article

Abstract: animals and generated a cooperative antitumor therapeutic effect by synergistically augmenting innate and adoptive antitumor immune responses. Our findings imply that a new combination therapy could improve the clinical response to anti-CTLA4 antibody therapy. Our findings also suggest that prescreening cancer patients for serum sMIC may help in selecting candidates who will elicit a better response to anti-CTLA4 antibody therapy.

Source: Science Advances

DOI: 10.1126/sciadv.1602133

Authors: Jingyu Zhang, Dai Liu, Guangfu Li, Kevin F. Staveley-O’Carroll, Julie N. Graff, Zihai Li, Jennifer D. Wu

Institutions: Medical University of South Carolina, University of Missouri, Oregon Health & Science University, OHSU Knight Cancer Institute, MUSC Hollings Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,500

Funders: U.S. Department of Defense, National Cancer Institute

Awards: Target MIC shedding to revive anti-tumor immunity, G4100110289, NKG2D superagonist co-stimulation to enhance adaptive immunotherapy of cancer, G5135251662, ENHANCING ANTI-CTLA4 IMMUNOLOGY THERAPY FOR PROSTATE CANCER WITH COTARGETING SOLUBLE NKG2D LIGAND, Targeting MIC shedding to revive host NKG2D-mediated immune response in prostate, An Orthotopic Murine Model of HCC: Immunotolerance and Prevention, G7618239942, G7722789702, Optimization of a novel cancer immunotherapeutic antibody for human use, G8008156719, Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy, Medical University of South Carolina - Cancer Center Support Grant

OpenAlex ID: W2615520798

FWCI: 1.929

Cites: 74

Cited by: 41

Related to: 10